Lenalidomide, Bortezomib, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: Encouraging Efficacy in High Risk Groups with Updated Results of a Phase I/II StudyPaul G. Richardson, Kenneth C. Anderson, Noopur Raje et al.|Blood|2008Cited by 68
Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) as Front-Line Therapy for Patients with Multiple Myeloma (MM): Preliminary Results of a Phase 1/2 Study.Paul G. Richardson, Kenneth C. Anderson, Sundar Jagannath et al.|Blood|2007Cited by 30